LENSAR, Inc.

Good morning, and thank you for your participation. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference will be recorded. I would now like to turn the call over to Lee Roth. Mr. Roth, please go ahead.

Thank you, Bridget. Good morning, and once again, welcome to the Lenzar Second Quarter 2021 Financial Results Conference Call. Earlier today, the company issued a press release providing an overview of its financial results for the quarter ended June 30th, 2021. And this press release is available on the investor relations section of our website at www.lenzauer.com. Joining me on the call today is Nick Curtis, Chief Executive Officer of Lenzauer, who will review the company's recent business and operational progress. Following his comments, Tom Staub, our chief financial officer, will provide an overview of the company's financial highlights for the second quarter before turning the call back over to Nick for closing remarks and opening the line for your questions. Before we begin, I'd like to remind you that today's conference call will contain forward-looking statements, including statements regarding future results, unaudited, and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties which may cause the company's actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place any undue reliance on these forward-looking statements. For additional information, including a detailed discussion of the company's risk factors, please refer to our documents filed with the SEC, which can be accessed on our website. In addition, this call contains time-sensitive information accurate only as of the date of this live broadcast, August 5th, 2021. Lenzar undertakes no obligation to revise or otherwise update any forward-looking statements to reflect events or circumstances after the date of this live conference call. With that said, it's now my pleasure to turn the call over to Nick Curtis.

Nick? Thank you, Lee, and good morning to everyone listening. Thank you for joining us on our second quarter 2021 conference call. I'm pleased to report that we have completed a very strong first half of 2021 as the markets in which we operate continued their gradual recovery from the COVID-19 pandemic. Evidence of this recovery can be seen in procedure volume in the second quarter, which increased 70% on a worldwide basis. While in the U.S., it was up over 140% as compared to the second quarter of 2020. In addition to increasing procedure volume, We're seeing an uptick in system placements as surgeons are once again beginning to invest in advanced technologies that can bring value to their practices by assisting in managing astigmatism and providing them with tools to manage better patient outcomes and practice efficiencies. In the second quarter, we sold three systems and leased an additional four systems compared to only four systems sold in the second quarter of 2020. Increasing the number of systems shipped and installed is also an indicator of future new procedure volume. While these trends are certainly encouraging, we're fully aware of the fluidity of the situation, particularly in light of the Delta variant and its effect in various regions across the world. Overall, we believe that the optimism displayed when we reported first quarter results in May was well-founded, and we remain enthusiastic about what the future holds for Lensar. Last quarter, I talked about medical congresses beginning to return to in-person venues and specifically mentioned the American Society for Cataract and Refractive Surgery, or ASCRS, which just recently took place at the end of July. Although meeting attendance was significantly below pre-COVID levels, quality content and the energy displayed by the attendees was there. I'm pleased to report that our LENSAR team was excited to showcase the present LENSAR laser system as well as the future. our ally system coming in 2022. The timing of the conference couldn't have been more ideal for us. First, as we announced a few weeks ago, studies utilizing our current generation technology were featured in a dozen different presentations during the meeting. In addition to our robust presence in the scientific program, there was a considerable practice and surge in interest in our current LENSAR laser system to include Streamline 4 and IntelliAXIS. On the exhibit hall floor, we performed multiple demonstrations for potential new partner customers, presently using competitive technologies that we're strongly considering changing based on others' references to Lensar's utility and performance. We came out of the conference with a significant number of new sales prospects for our current generation systems and look forward to further engagement with these potential partner customers in the weeks and months ahead. Equally important, however, was our private room. a virtual operating room featuring appointment-only demonstrations with our next-generation Ally adaptive cataract treatment system. We hosted more than 100 in-person demonstrations of the technology for leading cataract and refractive surgeons and other interested parties. The feedback we received from some of the most prominent surgeons in the field was overwhelmingly positive, providing strong affirmation that Ally addresses the needs in improving surgical workflow efficiencies provides surgeons with the ability to improve outcomes, as well as enhances the patient experience. In addition, we hosted a well-attended event for members of the ophthalmology press, during which they were able to see Ally firsthand. We addressed any questions they had so as to cover Ally in print, digital, and video content. Fundamentally, we had two goals for the ASCRS. To reinforce and demonstrate the premise that the Lensar laser system is the best femtosecond laser for physicians to treat their cataract and refractive cataract patients through unique and industry-leading core feature technologies, and also highlight the fact that these core and unique features will be taken to the next level with Ally. We believe that Ally represents the next great innovation in cataract and refractive surgery. It is a transformative system that integrates functions, including cataract density imaging, for patient tissue specific customized femtofragmentation to optimize the procedure to maximize cataract removal efficiency while significantly reducing the total energy delivered. Second, proprietary astigmatism guidance technology using true iris registration and data electronically transferred from multiple preoperative diagnostic devices. Three, a next generation femtosecond laser that is capable of treating four times faster in the cornea and two times faster in the lens. And number four, integration of a world-class phacoemulsification device in a small, complete, adaptive cataract treatment system that can be placed in any operating room or in-office surgical suite. This will revolutionize the surgeon and patient experience. We continue to make great progress in the development of Ally and are well on our way toward completing the remaining key milestones necessary for the 510 submission. We still plan to submit the 510K application to the FDA in the first quarter of 2022 with a commercial launch later in the year. Overall, we believe that Lensar is optimally positioned to leverage favorable industry trends to support the near-term growth and to truly disrupt the entire cataract treatment and removal industry with the release of Ally. That release and the next chapter of the Lensar story are drawing closer every day. Now, let me turn the call over to Tom. He's going to cover our financial highlights for the quarter. Tom?